Literature DB >> 3284458

Enzyme immunoassay to assess effect of antimicrobial agents on Toxoplasma gondii in tissue culture.

F Derouin1, C Chastang.   

Abstract

Toxoplasma gondii grown on MRC5 fibroblasts in 96-well tissue culture plates was tested for susceptibility to five antimicrobial agents. T. gondii growth was quantitated by an enzyme-linked immunosorbent assay, which was performed directly on the fixed cultures, using a rabbit anti-T. gondii immunoglobulin G as the first antibody and a phosphatase-labeled anti-rabbit immunoglobulin G as the second antibody. Optical density values were highly correlated with the number of T. gondii organisms in the Giemsa-stained cultures (r = 0.89), and an enzyme-linked immunosorbent assay was used to assess the effect of antimicrobial agents at various concentrations. For each drug, regression models were used to quantify the relationship between optical density values and antimicrobial agent concentrations in the cultures. A significant inhibitory effect was found with pyrimethamine and sulfadoxine for concentrations greater than or equal to 0.05 and 30 micrograms/ml, respectively. With spiramycin, a progressive increase in inhibition of T. gondii was observed for increasing concentrations from 1 to 100 micrograms/ml. Ornidyl (difluoromethylornithine) and (2R,5R)-6-heptyne-2,5-diamine, which are ornithine decarboxylase inhibitors, were found to have a marked inhibitory effect for concentrations greater than or equal to 25 and 2 mM, respectively. This proposed method was sensitive and easy to perform and does not require the use of radiolabeled compounds; since it allows experimental design on replicate cultures and can be partially automated, it thus may prove useful for the systematic screening of the activity of new compounds against T. gondii.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3284458      PMCID: PMC172164          DOI: 10.1128/AAC.32.3.303

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Congenital toxoplasmosis. A prospective study of 378 pregnancies.

Authors:  G Desmonts; J Couvreur
Journal:  N Engl J Med       Date:  1974-05-16       Impact factor: 91.245

2.  [Theoretical bases of the prevention by spiramycin of congenital toxoplasmosis in pregnant women].

Authors:  J P Garin; J Pellerat; R Woehrle
Journal:  Presse Med       Date:  1968-12-07       Impact factor: 1.228

3.  [Experimental toxoplasmosis in mice. Comparative activity of clindamycin, midecamycin, josamycin, spiramycin, pyrimethamine-sulfadoxine, and trimethoprim-sulfamethoxazole].

Authors:  J P Garin; B Paillard
Journal:  Ann Pediatr (Paris)       Date:  1984-11

4.  New micromethod to study the effect of antimicrobial agents on Toxoplasma gondii: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A.

Authors:  D G Mack; R McLeod
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

5.  The effect of trimethoprim and sulfamethoxazole on Toxoplasma gondii in vitro and in vivo.

Authors:  P L Grossman; J S Remington
Journal:  Am J Trop Med Hyg       Date:  1979-05       Impact factor: 2.345

6.  [A comparison of Ultrax, Diazil, Bactrim and Spiramycin in experimental toxoplasmosis in mice (author's transl)].

Authors:  H Coradello; S Kretschmer
Journal:  Wien Klin Wochenschr       Date:  1978-01-06       Impact factor: 1.704

7.  A method to evaluate the capacity of monocytes and macrophages to inhibit multiplication of an intracellular pathogen.

Authors:  R McLeod; J S Remington
Journal:  J Immunol Methods       Date:  1979-05-10       Impact factor: 2.303

8.  Potent effect of trimetrexate, a lipid-soluble antifolate, on Toxoplasma gondii.

Authors:  J A Kovacs; C J Allegra; B A Chabner; J C Swan; J Drake; M Lunde; J E Parrillo; H Masur
Journal:  J Infect Dis       Date:  1987-05       Impact factor: 5.226

9.  Inhibition of growth of Giardia lamblia by difluoromethylornithine, a specific inhibitor of polyamine biosynthesis.

Authors:  F D Gillin; D S Reiner; P P McCann
Journal:  J Protozool       Date:  1984-02

Review 10.  [Spiramycin ; therapeutic value in humans. (author's transl)].

Authors:  S Kernbaum
Journal:  Sem Hop       Date:  1982-02-04
View more
  18 in total

1.  High-throughput growth assay for Toxoplasma gondii using yellow fluorescent protein.

Authors:  Marc-Jan Gubbels; Catherine Li; Boris Striepen
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

2.  In situ enzyme-linked immunosorbent assay to quantitate in vitro development of Eimeria tenella.

Authors:  J A Olson
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

3.  Impact of spiramycin treatment and gestational age on maturation of Toxoplasma gondii immunoglobulin G avidity in pregnant women.

Authors:  M Lefevre-Pettazzoni; A Bissery; M Wallon; G Cozon; F Peyron; M Rabilloud
Journal:  Clin Vaccine Immunol       Date:  2007-01-03

4.  Anti-toxoplasma activities of 24 quinolones and fluoroquinolones in vitro: prediction of activity by molecular topology and virtual computational techniques.

Authors:  R Gozalbes; M Brun-Pascaud; R Garcia-Domenech; J Galvez; P M Girard; J P Doucet; F Derouin
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

5.  Use of Toxoplasma gondii expressing beta-galactosidase for colorimetric assessment of drug activity in vitro.

Authors:  D C McFadden; F Seeber; J C Boothroyd
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

6.  In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma gondii.

Authors:  S Romand; C Della Bruna; R Farinotti; F Derouin
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

7.  Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis.

Authors:  Stéphane Corvaisier; Bruno Charpiat; Cyril Mounier; Martine Wallon; Gilles Leboucher; Mounzer Al Kurdi; Jean-François Chaulet; François Peyron
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

8.  Localization of azithromycin in Toxoplasma gondii-infected cells.

Authors:  J C Schwab; Y Cao; M R Slowik; K A Joiner
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

9.  Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Toxoplasmosis Study Group.

Authors:  R McLeod; D Mack; R Foss; K Boyer; S Withers; S Levin; J Hubbell
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

10.  In vitro activities of 25 quinolones and fluoroquinolones against liver and blood stage Plasmodium spp.

Authors:  Nassira Mahmoudi; Liliane Ciceron; Jean-François Franetich; Khemais Farhati; Olivier Silvie; Wijnand Eling; Robert Sauerwein; Martin Danis; Dominique Mazier; Francis Derouin
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.